Duloxetine for PHN

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the investigators aim to investigate the preventive efficacy of prophylactic oral duloxetine during acute herpes zoster on postherpetic neuralgia and its safety.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital
• Collaborators: Baoding First Central Hospital; Beijing Tsinghua Chang Gung Hospital; Cangzhou Central Hospital; China-Japan Friendship Hospital; First Hospital of China Medical University; Fujian Provincial Hospital; Huai'an Second People's Hospital; Linfen Fourth People's Hospital; Peking University International Hospital; Qingdao Municipal Hospital (Group); Second Affiliated Hospital of Zhengzhou University; Shandong Provincial Hospital; Taiyuan Central Hospital of Shanxi Medical University; The People's Hospital of Fujian Province; The Second Affiliated Hospital of Zhengzhou University; Tianjin First Central Hospital; Tianjin Huanhu Hospital; Tianjin Medical University Second Hospital
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• ages more than 50 years;

• diagnosed with uncomplicated acute herpes zoster;

• presents with vesicles within 72 hours;

• has an average pain score of at least 40/100 mm on a visual analog scale (VAS, 0 = no pain, 100 = worst possible pain, at opposite ends of a 100-mm line).

Exclusion Criteria:

• refuses to participate or to provide written informed consent;

• Zung Self-Rating Depression Scale raw score of more than 50 points;

• herpes zoster that involves with head, neck, ocular, mucous membrane, cranial nerve, or central nervous system;

• has hemorrhagic or necrotizing lesions, satellite lesions, abnormal vesicles or acute retinal necrosis;

• has been on immunosuppressive therapy or mono- or multi-pharmacotherapy that involves any tricyclic antidepressant, valacyclovir, duloxetine or cytotoxic medications before acute HZ onset;

• has been diagnosed with hepatic, renal or immune dysfunction;

• during pregnancy or breastfeeding at the time;

• hypersensitivity to the study drugs;

• has contraindications to valacyclovir or duloxetine;

• HZ vaccinated.